Article
Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.
BioMed research international - 1 Jan 2017
Szopa Wojciech, Burley Thomas A, Kramer-Marek Gabriela, Kaspera Wojciech
Abstract excerpt
Glioblastoma (GBM) is a primary neuroepithelial tumor of the central nervous system, characterized by an extremely aggressive clinical phenotype. Patients with GBM have a poor prognosis and only 3-5% of them survive for more than 5 years. The current GBM treatment standards include maximal resection followed by radiotherapy with concomitant and adjuvant therapies. Despite these aggressive therapeutic regimens,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
